Navigation Links
AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
Date:3/12/2008

WILMINGTON, Del., March 12 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that it has completed patient enrollment in two pivotal Phase III studies for vandetanib, the company's investigational, once-daily oral anti-cancer drug, for the second-line treatment of non-small cell lung cancer (NSCLC). The two studies -- ZODIAC (ZACTIMA in cOmbination with Docetaxel In non-smAll cell lung Cancer) and ZEAL (ZACTIMA Efficacy with Alimta in Lung cancer) -- are the second and third of four ongoing studies to complete enrollment. Data from the studies are expected later this year and the broad development program is on track for a first regulatory submission in 2008.

ZODIAC is a randomized, double-blind, international, multi-center Phase III study to assess the efficacy of vandetanib 100mg once-daily plus the standard docetaxel chemotherapy versus docetaxel alone in 1,380 patients with locally advanced or metastatic NSCLC after failure of first-line anti-cancer therapy.

ZEAL is a Phase III parallel group, randomized, double-blind study evaluating vandetanib 100mg once daily plus pemetrexed 500mg/m2 (every 3 weeks) compared with placebo plus pemetrexed as second-line treatment in 510 patients with locally advanced or metastatic NSCLC who have failed first-line anti-cancer therapy.

The ZEST study, which is investigating vandetanib versus erlotinib, was the first Phase III study of vandetanib to complete enrollment in November 2007.

"NSCLC is an area of high unmet medical need, and we hope vandetanib will offer a beneficial new treatment option that may improve the lives of people with lung cancer," said Dr. Peter Langmuir, Medical Science Director at AstraZeneca.

ZODIAC and ZEAL are part of a broad Phase III clinical trial program designed to gain an understanding of how vandetanib may benefit people with lung cancer.
The other studies are:

-- ZEST (vandetanib versus erlotinib) enrollment is complete;
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
2. AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
3. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
4. Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development
5. AstraZeneca and Banner Alzheimers Institute Collaborate to Evaluate New Tool Targeting Alzheimers Disease
6. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
7. Pediatric Asthma Programs Featuring PARI Pharmas eFlow Acquired by AstraZeneca
8. BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing
9. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
10. D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99
11. Plurality Completes R&D of its HAL-256 Multicore Processor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Follow us on LinkedIn ... available in abundance in nature. These natural bio-based ... as shells of crustaceans. The significant commercial interest ... the high percentage of nitrogen present compared to ... industries owing to its exclusive properties such as ...
(Date:9/22/2014)... TORONTO , Sept. 22, 2014 ... announced that it has entered into a collaboration ... UHN,s Centre for Molecular Design and Preformulations (CMDP) ... The goal of the project is to increase ... proprietary buccal insulin spray product, thereby reducing the ...
(Date:9/22/2014)... , September 22, 2014 The ... a mixed note as the Dow Jones Industrial Average ... closed at 4,579.79, down 0.30%. The S&P 500 finished ... session, six out of ten sectors finished on a ... ended the day at 751.48, up 0.10%, with the ...
(Date:9/21/2014)... University of Basel in Switzerland have succeeded in ... molecule for the first time. These extremely weak ... molecular properties and may also contribute to the ... results were published in the scientific journal ... the interaction between matter and light, is probably ...
Breaking Biology Technology:Emergence of New Application Areas to Drive the Global Chitin and Chitosan Market, According to New Report by Global Industry Analysts, Inc. 2Emergence of New Application Areas to Drive the Global Chitin and Chitosan Market, According to New Report by Global Industry Analysts, Inc. 3Generex Collaborates with University Health Network for Buccal Insulin Project 2Generex Collaborates with University Health Network for Buccal Insulin Project 3Generex Collaborates with University Health Network for Buccal Insulin Project 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5Uncovering the forbidden side of molecules 2
... up a limbo line for the WTN readership. The question is ... high tech off the ground in your organization. , ,What got ... theft stories. Turns out the perps are not the archetypal Dorito-munching, ... In one case a bank gave its customer list to some ...
... alarums and excursions relevant to the world of Midwest ... ,Last week, the Midwest Venture Summit was held in ... 10 were sponsored by the Chicago chapter of the ... were registered to attend, an unofficial count estimated that ...
... could bring better, safer treatments to cancer patients worldwide might ... firm with more than 200 employees that has grown to ... its founder said. , ,The company is run by Thomas ... commercial when GE Medical cut off its funding for his ...
Cached Biology Technology:How low (tech) must you go? 2How low (tech) must you go? 3Midwest Venture Summit disappoints; Cato grades Midwest governors 2Midwest Venture Summit disappoints; Cato grades Midwest governors 3Midwest Venture Summit disappoints; Cato grades Midwest governors 4TomoTherapy considers IPO with medical-device business on the rise 2TomoTherapy considers IPO with medical-device business on the rise 3
(Date:9/21/2014)... CAMBRIDGE, MA -- In recent years, new strains of ... antibiotics. Each year, these superbugs, including drug-resistant forms of ... nationwide, and kill at least 23,000. Despite the urgent ... new classes of antibiotics in the past decade. , ... on these superbugs. Using a gene-editing system that can ...
(Date:9/21/2014)... A team of Stanford researchers has developed a protein ... to break away from original tumor sites, travel through ... in the body. , This process, known as metastasis, ... , "The majority of patients who succumb to cancer ... Jennifer Cochran, an associate professor of bioengineering who describes ...
(Date:9/19/2014)... Oklahoma biology professor will study the unique bioelectric signaling ... eventually benefit people,s health. The OU researcher is ... required to produce the signals used to map the ... at a rate of 500-600 discharges a second throughout ... electric fish are extreme, but necessary for survival. , ...
Breaking Biology News(10 mins):Battling superbugs 2Battling superbugs 3Battling superbugs 4Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4
... a common feature of prion disease-affected human, mouse, and ... Neena Singh and colleagues at Case Western Reserve University ... findings, published March 13 in the open-access journal ... of neurotoxicity in prion disorders, and novel avenues for ...
... Kansas State,University, with collaboration from Epitopix LLC, have ... E. coli O157 in beef cattle. ... the post-harvest food safety,aspect, whether it,s E. ... College of Veterinary Medicine. Thomson is the Jones,Professor ...
... German . The Aarhus University ... between the many conference participants and according to ... Kyoto was very successful in doing so: "I am ... will undoubtedly contribute significantly to the future climate debate ...
Cached Biology News:Iron is involved in prion disease-associated neuronal demise 2K-State researchers help Epitopix license the United States' first E. coli O157 vaccine for cattle 2Seven recommendations from Aarhus to COP15 2Seven recommendations from Aarhus to COP15 3
Vybrant® Multidrug Resistance Assay Kit...
...
... CultureWell cell culture systems provide an ... for staining and imaging. Each system ... standard optical-quality coverslips in cell culture ... sterile and ready to use. Individual ...
... of DETACHaBEAD Mouse CD4, polyclonal Sheep anti-Mouse ... from Dynabeads Mouse CD4 (L3T4). Detach ... Dynabeads Mouse CD4 using DETACHaBEAD Mouse CD4. ... downstream application including flow cytometry, functional studies ...
Biology Products: